REGENERX BIOPHARMACEUTICALS, Inc. (AM:RGN)
0.66
0.02 (2.94%)
| REGENERX BIOPHARMACEUTICALS, Inc. (AM:RGN) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $0.68 | 52 Week High | $1.95 | ||
| Open | $0.68 | 52 Week Low | $0.31 | ||
| Day High | $0.68 | P/E | N/A | ||
| Day Low | $0.63 | EPS | $-0.15 | ||
| Volume | 20,179 | ||||
| More RGN Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| ICCC | 2 | ICON | 2 |
| OMN | 2 | CIT | 2 |
| RMTI | 2 | DSCO | 2 |
| HOKU | 2 | VSR | 2 |
| HX | 2 | HWAY | 1 |
| ACLS | 1 | AMP | 1 |
Entities who have mentioned RGN
- 13D | View Related Stories »
- Roth Capital | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- Boenning & Scattergood | View Related Stories »
- Banc of America | View Related Stories »
- Crude Oil | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- Jefferies & Co | View Related Stories »
- Morgan Joseph | View Related Stories »
- Dividend | View Related Stories »
View All ReportsStreetInsider.com Reports on RGN
- REGENERX (RGN) Reports Study Data on Tb4 Drug Candidates
- Unusual 11 Mid-Day Movers 9/30: HOKU, ICCC, VSR, DSCO Higher; CIT, RGN, ICON, HX Lower
- Morning Movers 9/30: HOKU, ICCC, VSR, CFW, DSCO Higher; CIT, HX, RGN, ICON, APAB, RMTI Lower
- Regenerx Biopharma (RGN) Slumps as $4.7M Offering Announced
- Regenerx (RGN) Said Tb4 Significantly Improves Functional Recovery in MS Animal Model
View All Press ReleasesCompany Press Releases on RGN
- Promising Clinical Data with RegeneRx's Tb4 Drug Candidates Presented on Second Day of Thymosin Meeting
- Scientists Report Impressive Research Results with Tb4 on First Day of Thymosin Meeting
- RegeneRx Announces Offerings of Common Stock in Aggregate Amount of $4.7 Million
- RegeneRx's Tb4 Significantly Improves Functional Recovery in Multiple Sclerosis Animal Model
StreetInsider Reports on RGN by Category
View All BlogsBlogs on RGN
- Cash for Cardiovascular: Who Might Be Next?
- RegeneRx: A Beaten Down Biotech
- Biotech Week in Review: Regenerx Wins China Patent
- Market highlights for next week: Verizon, Starbucks to report
View All FilingsSEC Filings on RGN
- Form 10-Q REGENERX BIOPHARMACEUTIC For: Sep 30
- Form 8-K REGENERX BIOPHARMACEUTIC For: Oct 29
- Form SC 13D/A REGENERX BIOPHARMACEUTIC Filed by: Chaumiere Consultadoria & Servicos SDC Unipessoal LDA
- Form SC 13D/A REGENERX BIOPHARMACEUTIC Filed by: Inverlochy Consultadoria & Servicos L.D.A.
- Form SC 13D/A REGENERX BIOPHARMACEUTIC Filed by: CAVAZZA PAOLO
Comments on RGN
No comments are currently available.
